KR20240029029A - 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 - Google Patents

타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 Download PDF

Info

Publication number
KR20240029029A
KR20240029029A KR1020247002056A KR20247002056A KR20240029029A KR 20240029029 A KR20240029029 A KR 20240029029A KR 1020247002056 A KR1020247002056 A KR 1020247002056A KR 20247002056 A KR20247002056 A KR 20247002056A KR 20240029029 A KR20240029029 A KR 20240029029A
Authority
KR
South Korea
Prior art keywords
tasquinimod
amount
capsule
pharmaceutical
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247002056A
Other languages
English (en)
Korean (ko)
Inventor
한스 반만
Original Assignee
액티브 바이오테크 에이비
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액티브 바이오테크 에이비 filed Critical 액티브 바이오테크 에이비
Publication of KR20240029029A publication Critical patent/KR20240029029A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247002056A 2021-07-02 2022-06-30 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법 Pending KR20240029029A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21183481.7 2021-07-02
EP21183481 2021-07-02
PCT/EP2022/068063 WO2023275248A1 (en) 2021-07-02 2022-06-30 A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product

Publications (1)

Publication Number Publication Date
KR20240029029A true KR20240029029A (ko) 2024-03-05

Family

ID=76764937

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002056A Pending KR20240029029A (ko) 2021-07-02 2022-06-30 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법

Country Status (10)

Country Link
US (1) US20240277693A1 (https=)
EP (1) EP4363404A1 (https=)
JP (1) JP2024524158A (https=)
KR (1) KR20240029029A (https=)
CN (1) CN117500790A (https=)
AU (1) AU2022303084A1 (https=)
CA (1) CA3221689A1 (https=)
IL (1) IL309486A (https=)
MX (1) MX2023014668A (https=)
WO (1) WO2023275248A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn
WO2025228998A1 (en) * 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CN105367492B (zh) * 2014-08-28 2018-07-03 杭州普晒医药科技有限公司 他喹莫德的晶型及其制备方法、其药物组合物和用途
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
BR112023000892A2 (pt) 2020-07-23 2023-02-07 Univ Erasmus Med Ct Rotterdam Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor

Also Published As

Publication number Publication date
MX2023014668A (es) 2024-01-12
EP4363404A1 (en) 2024-05-08
WO2023275248A1 (en) 2023-01-05
AU2022303084A1 (en) 2024-01-25
US20240277693A1 (en) 2024-08-22
CA3221689A1 (en) 2023-01-05
CN117500790A (zh) 2024-02-02
IL309486A (en) 2024-02-01
JP2024524158A (ja) 2024-07-05

Similar Documents

Publication Publication Date Title
JP6861758B2 (ja) Ｈｉｆプロリルヒドロキシラーゼ阻害剤の医薬製剤
JP7667568B2 (ja) 複素環キナーゼ阻害剤及びその使用
WO2024061267A1 (zh) 一种药物组合物及其制备方法和用途
EP3056205A1 (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
US20240307398A1 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
Herben et al. Oral topotecan: bioavailability and effect of food co-administration
KR20240029029A (ko) 타스퀴니모드를 함유한 약학적 제품 및 이러한 제품의 순도 평가 방법
JP2013079234A (ja) Ｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミドの医薬組成物
JP7445597B2 (ja) キノロン類似体及びそれらの塩、組成物、ならびにそれらの使用方法
TW202133856A (zh) 涉及二芳基巨環化合物之組合療法
EP2826477A1 (en) Solid composition of amino carboxylate salt
CN112672789A (zh) 用于治疗癌症的5-乙酰氨基甲基-噁唑烷酮衍生物
BR112016016021B1 (pt) Composição farmacêutica, seu uso, formulação de dosagem oral e método para preparar comprimido por compressão direta em formulação de dosagem única
CN116367831A (zh) 用于治疗由kdm1a介导的疾病的药物配制品
CN104447771A (zh) 一种稳定的马来酸阿塞那平化合物
KR20230154227A (ko) 치료적 유효 용량의 malt1 억제제 jnj-67856633(1-(1-옥소-1,2-다이하이드로아이소퀴놀린-5-일)-5-(트라이플루오로메틸)-n-(2-(트라이플루오로메틸)피리딘-4-일)-1h-피라졸-4-카르복스아미드)을 사용하는 병태의 치료 방법
EP3995134A1 (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
RU2462248C2 (ru) Стабильная фармацевтическая композиция, содержащая водорастворимую соль винфлунина
JP2021523195A (ja) Ｈｃ−１１１９製剤及びその製造方法と使用
JP2024524158A5 (https=)
CN121969357A (zh) Mrtx1133药物组合物
EP4346773B1 (en) A plurality of tasquinimod particles and use thereof
CN105646520A (zh) 一种稳定的艾日布林化合物
US12285412B1 (en) Organoselenium benzimidazole compounds for treating cancer
EP4656205A1 (en) Method for treating canine b cell lymphoma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250612

Comment text: Request for Examination of Application